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Abstract: While head and neck squamous cell carcinomas (HNSCC) are marginally decreasing due
to the reduction in exposure to the major risk factors, tobacco and alcohol, the incidence of high-risk
human papillomavirus (HPV)-positive oropharynx squamous cell carcinomas (OPSCC), especially
those in the tonsil and base of tongue subsites, are increasing. Patients with the latter are younger,
display a longer overall survival, and show a lower recurrence rate after standard-of-care treatment
than those with HPV-negative OPSCC. This may reflect an important role for immune surveillance
and control during the natural history of the virally driven tumour development. Immune deviation
through acquisition of immune-suppressive factors in the tumour microenvironment (TME) is
discussed in relation to treatment response. Understanding how the different immune factors are
integrated in the TME battleground offers opportunities for identifying prognostic biomarkers as
well as novel therapeutic strategies. OPSCC generally receive surgery or radiotherapy for early-
stage tumour treatment, but many patients present with locoregionally advanced disease requiring
multimodality therapies which can involve considerable complications. This review focuses on the
utilization of newly emerged immune checkpoint inhibitors (PD-1/PD-L1 pathway) for treatment
of HNSCC, in particular HPV-positive OPSCC, since they could be less toxic and more efficacious.
PD-1/PD-L1 expression in the TME has been extensively investigated as a biomarker of patient
response but is yet to provide a really effective means for stratification of treatment. Extensive testing
of combinations of therapeutic approaches by types and sequencing will fuel the next evolution of
treatment for OPSCC.
Keywords: oropharyngeal squamous cell carcinomas (OPSCC); human papillomavirus (HPV); tu-
mour microenvironment (TME); immune checkpoint inhibitors; programmed death receptor-1 (PD-1)
and ligand -1(PD-L1); T cell effectors; myeloid-derived suppressor cells (MDSC); macrophages;
dendritic cells (DC)
1. Introduction
Head and neck cancers originating in the oral cavity, larynx, pharynx (hypopharynx,
nasopharynx, or oropharynx), and in the sinonasal tract are 90% squamous cell carcinomas
(SCC) [1–4]. This is the eighth most common malignancy worldwide in 2018, and overall
survival (OS) for localized cancers is more than 90% for salivary gland and mucosal lip
sites but closer to 60% for laryngeal and hypopharyngeal sites [5]. The principal associated
risk factors are tobacco use, alcohol consumption, high risk (HR) human papillomavirus
(HPV) infection (for OPSCC), and Epstein-Barr virus (EBV) infection (for nasopharyngeal
squamous cell carcinoma) [1–4]. When the upper aerodigestive tract is chronically exposed
to these carcinogenic elements, dysplastic lesions can develop in the oropharyngeal mu-
cosa and such premalignant neoplasia is a precursor for malignant tumours. The relative
prevalence of these risk factors contributes to the variations in the observed distribution of
head and neck squamous cell carcinomas (HNSCC) in different areas of the world [1–4].
Viruses 2021, 13, 1234. https://doi.org/10.3390/v13071234 https://www.mdpi.com/journal/viruses
Viruses 2021, 13, 1234 2 of 27
Unsurprisingly, HNSCC are a very heterogenous group of cancers which demonstrate dif-
ferent pathologies, prognoses, and treatment options [5]. Genomic analysis of HNSCC has
provided comprehensive lists of associated mutations/genetic changes (single nucleotide,
confined insertions/deletions, larger alterations including gains and losses from arms of
or entire chromosomes) [2,6]. The picture that emerges for HPV-negative HNSCC is of
some key driver somatic gene mutations, with each generally associated with considerably
less than a quarter of tumours (with the exception of TP53, which is present in a majority
(72%)), which then are manifest on a background of other diverse, including passenger,
mutations. Most of the driver events inhibit the action of tumour suppressor functions on
the cell cycle (p16INK4A; p53), survival (PTEN), WNT signalling (protocadherinFAT1; LIM
domain-containing protein AJUBA; NOTCH1), and epigenetic regulation (histone-lysine
N-methyltransferases KMT2D and NSD1). Acquisition of oncogenic action on the cell cycle
(G1-S-specific cyclinD1), epidermal growth factor receptor (EGFR), and survival have also
been documented in some subsets of HPV-negative HNSCC [2,6].
2. Oropharyngeal Squamous Cell Carcinomas (OPSCC)
The incidence of HNSCC located at most oral sites is actually marginally decreasing
because of the reduced exposure to the tobacco and alcohol risk factors associated with its
development. By contrast, the incidence of OPSCC associated with HR HPV is increasing,
particularly in young men, which is most apparent in Northern Europe and North America
and believed to be the consequence of oral sexual behaviour [5,7]. For SCC originating
in the oropharynx, tonsil, and base of the tongue (OPSCC), HR HPV, principally HPV 16,
accounts for >80% of the tumours [8,9]. Importantly, patients with HPV16-positive OPSCC
display a longer OS and a lower recurrence rate after SOC treatment than patients with
HPV-negative OPSCC [7]. Since HPV-related OPSCC behaves differently as a disease when
compared to HPV-negative OPSCC, a separate staging system has been developed [10,11].
The assignment to HPV-positive is frequently inferred from p16 immuno-histochemistry
whereby the expression of p16 is constitutively unregulated by HPV oncogene suppression
of Rb [12]. This type of measure is not fool-proof and additional, more direct, measures of
HPV through nucleic acid detection can significantly improve specificity, but gold-standard
detection of hr HPV oncogene RNA is unfortunately not regularly utilised [13].
For TNM staging (see Legend Table 1), while the T categories for HPV-positive and
HPV-negative OPSCC are similar, a T0 level (unknown primary) category is only used
in p16-positive metastatic nodes, where the primary is presumed an OPSCC, and the
T4b category has been removed from p16-positive OPSCC. For clinical N staging of p16-
positive disease: N1 is ipsilateral nodes (one or multiple), but none larger than 6 cm, N2 is
contralateral or bilateral nodes less than 6 cm, and N3 is when nodes are greater than 6
cm. Pathological staging is only available to patients where surgery is possible, and for
HPV-related (p16-positive) OPSCC the number of positive nodes between 1 and 4 vs. 5 or
more impacts outcome, so this is reflected in pN staging. A summary of the clinical and
pathological prognostic stage groups is shown in Table 1 [11].
The natural history of HPV-mediated carcinogenesis in HNSCC is not precisely docu-
mented. However, in squamous epithelium of the transformation zone of the cervix, about
20% of hr HPV infections result in dysplastic lesions, and the major risk factor for cancer
progression is persistent infection [14]. In cases where the normal viral life cycle is aborted
and expression of the viral oncogenes E6 and E7 is elevated (e.g., through integration
of the virus in cell genome), cell proliferation is stimulated. This virally driven cellular
proliferation is causally linked to malignant transformation through unregulated E7 expres-
sion degrading the host cell retinoblastoma pocket proteins (RB), inducing S-phase-related
molecular changes, with viral E6 binding to and degrading p53 to prevent apoptosis of
unscheduled S-phase entry [15]. This leads to a reduced control of the cell cycle which
would usually allow for DNA repair of any genetic errors. Any accumulation of mutations
can provide advantage for transformation to high-grade cervical intraepithelial neoplastic
lesions [15,16].
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Table 1. AJCC prognostic clinical or pathological stage groups for HPV-related (p16-positive) oropharyngeal cancers [10,11].
Stage Clinical Pathological
I T0N1M0, T1N0M0, T1N1M0, T2N0M0 or T2N1M0 T0N1M0, T1N0M0, T1N1M0, T2N0M0 or T2N1M0
II T0N2M0, T1N2M0, T2N2M0, T3N0M0, T3N1M0 orT3N2M0
T0N2M0, T1N2M0, T2N2M0, T3N0M0, T3N1M0,
T4N0M0 or T4N1M0
III T0N3M0, T1N3M0, T2N3M0, T3N3M0, T4N0M0,T4N1M0, T4N2M0 or T4N3M0 T3N2M0, or T4N2M0 IV Any T, any N and M1
IV Any T, any N and M1
Legend: A general categorization assigns cancers as stage 0 (abnormal cells are present but with no spread); stages I-III (increasing size and
local spread), and stage IV (spread to distant sites). Additional information is provided by the TNM system: T refers to the size and extent
of the main or primary tumour, N to the number of nearby lymph nodes that have cancer, and M to whether the cancer has metastasized.
Further information is reflected in numbered subdivisions. Thus TX: main tumour cannot be measured; T0: primary tumour cannot be
found; and T1, T2, T3, T4: refer to the size and/or extent of the main tumour. The higher the number after the T, the larger the tumour or the
more it has grown into nearby tissues. Tumours may be further divided to provide more detail, such as T3a and T3b. Likewise, for regional
lymph nodes (N): NX: cancer in nearby lymph nodes cannot be measured; N0: there is no cancer in nearby lymph nodes; N1, N2, N3: refer
to the number and location of lymph nodes that contain cancer. The higher the number after the N, the more lymph nodes that contain
cancer. For distant metastasis (M): MX: metastasis cannot be measured; M0: cancer has not spread to other parts of the body; M1: cancer
has spread to other parts of the body. Recent modifications in the T classification for some tumours include the depth of invasion (DOI)
of the primary (increase category by 1 level for each 5 mm of depth) and new refinements on the N categorisation utilising pathological
(histology) and/or clinical (imaging) to measure extra-nodal extension (ENE). Cut-offs define changes in staging level or a new sublevel.
Pathology-driven measures can be assessed and validated retrospectively, but this is more difficult for clinically based approaches for there
is no precedent and the imaging modalities have very different sensitivities and specificities. For example, a clinical estimation of depth of
invasion may overestimate by 1–2 mm, and contribution to size of lesion through inflammation or ulceration cannot be distinguished.
The productive versus transforming fate of an HPV infection may be dependent on the
infected cell type of origin. For example, it has been suggested that specific single-layered
epithelial cells of embryonic origin at the cervical squamocolumnar junction constitute
highly susceptible cells for transforming infections and the origins of cancers [17]. For OP-
SCC, no obvious virus-infected premalignant lesions have yet been identified, but it is
very likely that the natural history of oncogenesis is similar. As documented for cervical
cancer, molecular changes in genes of the PI3K pathway are the most frequent genetic
alterations found in HPV-driven HNSCC [6,18]. The PI3K signalling pathway affects trans-
lation and transcription of multiple targets that are involved in proliferation, survival, and
motility [19]. However, while PIK3CA alterations appear more common in HPV-positive
HNSCC, these are also detected in HPV-negative OPSCC; oncogenic PI3K signalling seems
to constitute a driver for many HNSCC, independent of HPV involvement [6]. Genomic
profiling of HPV-positive OPSCC shows evidence of heterogeneity in patterns of altered
gene expression [20].
3. Standard of Care (SOC) for OPSCC
Surgical treatment, especially with recent advances in transoral robotic surgery of
OPSCC, can sometimes be curative if the tumour is relatively small, has not spread, and is
easily accessible, although these procedures are not without risks and quality of life seque-
lae [21]. Unfortunately, a majority of OPSCC patients present with locoregionally advanced
(LA) disease for which a multimodality therapeutic approach including radiotherapy (RT)
or chemo-RT (CRT) with or without surgery is usually employed [22–24].
CRT avoids surgery-associated risks, but there are frequently other complications in-
cluding widespread tissue damage/toxicity in the head/throat region, including significant
impacts for speech and swallowing, plus increased risk for secondary malignancies [25].
Furthermore, the use of cetuximab, a monoclonal antibody against epidermal growth factor
receptor (EGFR), in combination with cisplatin or carboplatin and 5-fluorouracil (5FU) as a
first-line treatment of recurrent/metastatic (R/M) HNSCC (EXTREME) has some utility
with improved overall survival compared to platinum plus 5FU treatment with a response
rate in about one third of patients [26]. Clearly there is a requirement to minimise toxicities
and avoid the late complications, particularly in the younger patients with HPV-positive
OPSCC, with its better prognosis [7,27]. To summarize, OPSCC generally receive RT
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or surgery for early-stage tumour treatment with combination therapies used for more
advanced cancers.
Consequently, in spite of improvements in diagnostics, treatment, and surveillance,
the 5-year progression-free survival (PFS) of patients with HPV-negative OPSCC with LA
disease is ~40–50%, and survival rates for R/M disease have not significantly changed over
the past years [5]. Advanced-stage HPV-positive OPSCC patients have five-year survival
rates of 75–80%, vs. <50% among patients with similarly staged HPV-negative tumours [7].
With R/M disease having such a poor prognosis there is clearly an urgent need to identify
biomarkers for detection of early disease, accurate prediction of prognosis, and appropriate
selection of therapy.
In 2018, The National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology (NCCN, USA) defined some modifications of treatment plans for p16-positive vs.
HPV-negative OPSCCs [28]. However, the options recommended in most cases did not vary
except where as an alternative to definitive RT alone or surgery alone, treatment with RT
plus systemic therapy was recommended for T1 N1 p16-negative but not for p16-positive
tumours with a single node ≤ 3 cm. Overall, all OPSCC should receive RT or surgery
for early-stage tumour treatment with combination therapies used for more advanced
cancers. For example, platinum-based chemotherapy (CT) with RT reduces HNSCC and
the OPSCC subgroup patient mortality by 26%, yielding an 8% absolute 5-year survival
benefit [29]. However, using cisplatin plus RT showed significant increases in both acute
and late toxicity. There was a lot of enthusiasm to test whether a de-escalation of SOC
therapies could deliver a significant reduction in the side effects (toxicity) of the treatments
plus an improvement in quality of life, but without any loss of efficacy. The logic was that
the distinct tumour biology of HPV-positive OPSCC with their better prognosis derived
from a possibly higher treatment sensitivity.
Several early phase clinical trials investigated whether response to induction CT could
select patients with stage III-IV HPV-positive OPSCC for reduced-dose radiation. Indeed,
patients with a complete response to induction CT retained cancer control with reduced
radiation doses, but with reduced swallowing and nutritional problems [30,31]. Additional
trials are probing de-escalated treatments for HPV-positive OPSCC. These include reduced-
dose radiation and/or CT, stratifying by response to induction CT, stratification for any
follow-up loco-regional therapy, efficacy of CT or RT as alternatives to surgery, minimally
invasive transoral robotic surgery using pathology to stratify patients for de-escalation (and
using targeted therapies) [28]. One such randomised, prospective clinical trial recruited
only patients with LA HPV-positive OPSCC and was designed to investigate non-inferiority
of efficacy accompanied by reduction in acute and late therapy toxicity where cetuximab
was substituted for cisplatin [32]. Previous work had provided support for the value of
cetuximab when added to RT for locoregional control and survival in LA HNSCC [30].
Unfortunately, the RT plus cetuximab treatment was inferior to SOC (RT, cisplatin) and
increased the risk of cancer progression and death and loss of locoregional control without
any significant influence on overall toxicities [32]. It is worth pointing out, however, that
this needs to be tested in HPV-negative OPSCC where EGFR amplification, overexpression,
and downstream signalling are more frequent in contrast to HPV-positive cancers, where
mutations downstream of EGFR (e.g., activating in PIK3CA) are more frequent and could
mediate resistance to cetuximab.
The recognition of the potential of immunotherapies in cancer treatment, including
checkpoint inhibitors, has stimulated the investigation of biomarkers relating to immune
parameters and their importance in HNSCC. The next sections discuss the evidence of
immune dysfunction in OPSCC and the use of checkpoint inhibitors in treatment. The value
of immune biomarkers assessments in the optimal deployment of treatments involving
checkpoint inhibitors for OPSCC treatment, especially due to the differences in outcome
depending on HPV status, is also discussed.
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4. Biomarkers in OPSCC
Investigation and validation of any potential tumour biomarkers could be of great
value in prognostication and therapy selection and refinement for patients with OPSCC.
There are challenges in utilising the extensive genomic information for biomarker applica-
tion which arise from heterogeneity in the patterns of expression both within individual
tumours and between HNSCC tumours. Differences in clinical outcomes for OPSCC are
likely to involve multiple factors including differential radio/chemosensitivity and genetic
heterogeneity [33–35], but it is also possible that activation of local oropharyngeal immunity
has a role in limiting the spread of the disease and/or enhancing response to therapy.
The important role of the immune system in the surveillance and control of neoplasia
is now widely recognized [36,37]. Additionally, the subversion of such immune control
through acquisition of immune suppressive factors in the tumour microenvironment (TME)
is established as significant to cancer progression and poor treatment response, but under-
standing this also offers therapeutic opportunities [38–41]. The complex interactions at play
in the natural history of an OPSCC are reflected in the emerging gene-expression profiles,
which distinguish epithelial-mesenchymal transition (EMT), immune-related, keratinocyte
differentiation, and oxidation stress factors with possible links to differential outcomes
under investigation [4]. Detailed investigations of the types and proportions of immune
cells and their interactions in the TME and any links to clinical performance following
different treatments could provide the means for improved patient management. Any prac-
tical biomarker must have sufficient specificity and sensitivity, allowing clinically useful
positive and/or negative predictive value, and be implementable in the clinical setting.
5. Immune Deviation
Lessons from Cervical Neoplasia
The lack of identifiable or accessible dysplastic precursor lesions limits our under-
standing of the natural history of HPV-driven neoplasia in OPSCC. However, based on
our knowledge of HPV-associated cancers of the anogenital tract, in particular cervical
neoplasia, there is clear evidence that the hr HPV infection of the target epithelium and
the viral oncogene expression undermines the functioning of key elements of the innate
immune system. This begins with a reduction of antigen-presenting cells which allows
early virus immune evasion and persistence of infection. Over time, a multitude of in-
teracting and self-reinforcing events actioned through modulation of different immune
receptors, chemokine, and cytokine responses combine to generate an immune-suppressive
microenvironment. This includes infiltration of immune-suppressive populations of Tregs,
Th17, myeloid-derived suppressor cells (MDSCs), and upregulation of immune checkpoint
receptor/ligand pathways [40–42]. All these changes constitute an immune deviation
which can critically undermine the key T cell effector mechanisms capable of tumour
control and elimination.
6. Immune Infiltration of OPSCC
6.1. T-Lymphocytes
Many investigations of whether the densities of various TME-infiltrating immune cells
correlate with clinical outcomes in HNSCC have been performed [43–46]. Unsurprisingly,
the inherent heterogeneity of the HNSCC with different prognoses plus the diversity and
quality of immunohistochemical (IHC) analyses performed have yielded a wide range of
results. A priori, the acquisition of diverse and cumulatively immunosuppressive factors
will impact on tumour control and clinical performance in therapy. The question here is
whether there are biomarkers from this set of parameters that can be useful for patient
management, etc. Here, the focus is on OPSCC, where there are clear differences in patient
clinical outcomes for HPV-positive and HPV-negative tumours.
Overall, there is a consensus for high levels of CD8+ and CD4+ T lymphocytes associat-
ing with better clinical responses to SOC treatment [46]. Thus, higher levels of infiltrating T
cells have been documented in HPV-positive compared with HPV-negative OPSCC [47–50]
Viruses 2021, 13, 1234 6 of 27
(but not always [51,52]). However, when an increased T cell density was found in HPV-
positive OPSCC it did not necessarily correlate with improved outcome. Interpretation
of the results would be easier if there was consistency in the HPV typing methods and
the techniques and reagents used to measure different immune factors in the TME. These
should in particular include the precise location (tumour or stroma), the functionality of
potential effectors, or the presence of other influences (secreted or cellular) which might
counteract any anti-tumour activity. A study that assessed the relative infiltration in the
tumour and the associated stroma reported a significant correlation of stromal infiltration
by CD8+ T cells with better clinical outcome in HPV-positive OPSCC [43]. Evidence from
cervical neoplasia has associated T cell infiltration of the epithelium as the key to lesion
regression [53] and that the stroma may be the point of entry for such effector cells [54,55],
possibly associated with activation of relevant gene expression in the stroma [56].
Of course, an alternative tumour-driven inflammatory influence can lead to the secre-
tion of cytokines able to recruit other types of immunosuppressive cells to the TME. For
example, Tregs contribute to control of immunological tolerance but can also play a role in
facilitating cancer progression through suppression of anti-tumour immune responses. For
HNSCC, including OPSCC, there is conflicting evidence regarding their role in suppressing
tumour immunity and survival [57]. In part, this reflects the inadequacy of the markers
used to identify Tregs either in the tissues or the peripheral blood plus lack of information
on their functional status [46].
The inflammatory milieu of the TME plus the relative proportions of, e.g., T cell
effector or suppressor cells populations are likely to influence the clinical outcomes of
the patients. For example, studies have associated higher interferon gamma but lower
interleukin-4 and transforming growth factor-beta levels in HPV-positive compared to HPV-
negative OPSCC [58]. The presence in the TME of IFN-gamma-producing CD4+ and CD8+
T cells, inferred from expression of the transcription factor Tbet, has shown association
with improved OS [45,59], while the presence of non-T cell IL-17-producing cells was
linked to poorer survival [60]. Paradoxically, in one study, Tbet-positive Tregs were shown
to accumulate in HPV16-positive OPSCC and the patients showed improved survival
to SOC therapy [61]. Importantly, in such good responder patients, the Tbet-expressing
intratumour populations of Tregs correlated with the levels of Tbet-positive CD4+ and
CD8+ T cells and the detection of HPV-specific T cells. Such results are consistent with the
characteristics of a T helper 1 type biased immune response with balance of inflammatory
conditions supporting anti-tumour activity [61].
The functionality of anti-tumour effector T cells in the TME can also be compromised
by alterations in HLA expression by the tumour target cells [62]. In HPV-driven cancers,
overexpression of E6/E7 oncogenes facilitates genomic instability, and any generated
mutations that cause HLA class I down-regulation by tumour cells could be selected as a
means for immune escape. However, such variation in HLA class I expression in HNSCC
does not appear to correlate with clinical outcome [63,64]. Once again, the individual
influence of a gross measure like HLA class 1 expression may be compromised by the
heterogeneity and the integrated effect of a multiplicity of contributing factors. Interestingly,
upregulation of HLA class II expression on HPV-positive OPSCC has been correlated with
improved survival of such patients, consistent with a role for CD4 T cells in the control
of OPSCC [65].
6.2. Myeloid Cells
Notably, the particular flavour of the inflammation can also influence the myeloid cell
infiltrate and its functionality in the TME including by differentiation into macrophages,
myeloid-derived suppressor cells (MDSC), or antigen-presenting dendritic cells (DC).
Thus, when blood monocytes attracted to the TME differentiate into tumour-associated
macrophages (TAM) they can provide either anti-tumour (M1) or tumour-promoting
activity (M2) as driven respectively by the local levels of IFN gamma versus IL-4/IL-13 [66].
Furthermore, various secretions (TGF-beta, vascular endothelial growth factor (VEGF),
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IL-6, IL-10, prostaglandin E2 (PGE2), and chemokines) by the M2 macrophages act to
promote tumour metastasis and Treg expansion with concomitant suppression of effector T
cell activity [67]. Most importantly, in response to local IFN gamma production or hypoxia,
TAM can upregulate inhibitory ligands of the immune checkpoint pathways which can
limit anti-tumour T cell activity (see below). It is no surprise that there are investigations
of OPSCC macrophage tumour infiltration and clinical outcome which support either a
role in tumour control [67] or in promotion [65]; this can also differ in HPV-negative vs.
HPV-positive tumours [63]. This lack of clarity most likely derives from the difficulty of
distinguishing the functionality of macrophages in the context of all the other contributing
factors. Some commonality for a positive contribution by TAM is probably favoured by the
Th1 cell response flavour of local immunity in the TME [67].
MDSCs can be recruited from the blood or generated locally by arresting monocyte
differentiation at an immature point. They can accumulate in different places in response
to proinflammatory molecules (PGE2, IL-1β, IL-6, VEGF, S100A8/A9 proteins, and the
complement component C5a) produced by tumour cells or by host cells in the TME [68].
MDSCs suppress anti-tumour immunity through a variety of diverse mechanisms. T
cell activation is suppressed by production of arginase and ROS, the nitration of the T
cell receptor (TCR), cysteine deprivation, and the induction of Tregs. Innate immunity is
impaired by the down-regulation of macrophage-produced IL-12, the increase in MDSC
production of IL-10, and the suppression of natural killer (NK) cell cytotoxicity. Antigen
presentation is limited by the expansion of MDSC at the expense of DC. Defining the
monocytic MDSC phenotype requires multiple markers (CD14+ HLA-DR-CD33+ CD11b+)
that are difficult to assess in TME in situ but can be assessed by flow cytometry to enu-
merate circulating levels [69,70]. High systemic levels of MDSC have been associated
with recurrence in OPSCC patients [71], and a variety of depletion strategies are being
investigated to potentially boost immunotherapeutic strategies [72]. A recent study has
highlighted the need to monitor the dynamics of monocyte differentiation in the context of
other populations of peripheral blood mononuclear cells (PBMC) [73]. Thus, an elevated
monocyte count was detected before the initiation of treatment in the PBMC of OPSCC
patients which correlated with poor prognosis. Dynamic changes in monocyte subsets were
documented involving the immune checkpoint ligand PD-L1 expression on monocytes and
monocyte-derived MDSCs. Other studies have investigated peripheral blood measures of
T effector lymphocytes, but this has not generally correlated with the levels in the TME or
reliably predicted clinical outcomes [51].
Finally, monocytes recruited into the TME can also differentiate into DCs and high
numbers can be associated with good clinical outcomes [74]. As the primary antigen-
presenting cells in the tumour, they can promote the numbers and sustained functionality
of infiltrating cytotoxic T lymphocyte responses. It is generally thought that DCs in tu-
mours capture tumour antigens and migrate to draining lymph nodes, where they prime
and activate tumour-specific T cells. Memory and effector CTLs return to the tumour
to perform immunosurveillance activities limiting tumour development and/or progres-
sion. Infectious disease models have established that antigen-experienced T cells require
cognate interactions with tissue DCs to expand in situ and achieve full effector functions.
Unfortunately, due to the immunosuppressive nature of the TME, plus their plasticity,
tumour DCs are often dysfunctional, which in turn facilitates immune evasion. Indeed, it
appears that the number, phenotype, and function of DCs can alter as a cancer develops
with tumour-infiltrating DCs, macrophages, MDSCs, and T cells densities increasing but
with a change from an immunostimulatory to an immunosuppressive DC phenotype [75].
7. Immune Checkpoint Pathways
Multiple inhibitory (e.g., PD-L1, TIM-3, LAG-3, CD200, and CTLA4) and activating
(4-1BBL, ICOS-L, CD80, and CD86) immune regulatory molecules influence the activation,
differentiation, and proliferation of T cells. T cell interactions with immature DCs can
lead to T cell tolerance through various mechanisms, including deletion, anergy, and the
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generation of regulatory T cells [76,77]. Importantly, a class of inhibitory agents targeting
some of these immune checkpoint pathways has been associated with sustained tumour
responses in a variety of cancers [78]. The receptor-programmed death−1 (PD-1) interacting
with its ligand PD-L1 is recognized as one dominant negative regulator axis of anti-tumour
effector function whereby the interaction of PD-L1 leads to PD-1-mediated T cell exhaustion
and inhibition of anti-tumour cytotoxic T cells. The stimulation of tumour specific T cells
in the local tumour environment releases interferon gamma and this upregulates PD-L1 on
the local tumour and other cells. This type of homeostatic mechanism is usually deployed
to limit inflammation in a resolving lesion, but in the chronic tumour situation it can be
subverted to compromise T cell function through adaptive immune resistance as discussed
in more detail by others [79]. For more information on the subject, please also see a recent
excellent review on emerging concepts in PD-1 checkpoint biology [80].
Blockade of the PD-1/PD-L1 axis by antibodies can reverse this immune suppression,
and such single-agent therapies are now licensed treatment for several types of cancers [75,
81]. Expression of PD-L1 in tonsillar crypts has led to speculation that it might facilitate
HPV infection at these sites and has therefore encouraged the use of PD-1 inhibitors in
patients with HPV-positive tumours [82]. Some studies have shown that upregulation
of PD-1 and/or PD-L1 in OPSCC is linked to stronger immune infiltration and a good
prognosis following SOC treatment, possibly reflecting an effective ongoing anti-tumour
immune response [83–86]. However, a recent meta-analysis of immunohistochemistry
(IHC) analyses for PD-L1 expression showed a positivity rate of 36–48% for HNSCC; but
while HPV-positive tumours showed a relatively increased PD-L1 expression, in neither
case was the PD-L1 level linked with OS [87].
8. Licencing of Immune Checkpoint Inhibitors for Treatment in HNSCC
Building on encouraging early phase clinical studies in HNSCC, late phase III trials
have now executed validation studies of several immune checkpoint inhibitor antibodies
that block the PD-1/PD-L1 axis for the treatment of R/M HNSCC patients that failed a
platinum-based therapy [88]. The illustrative results are summarized in Table 2 for two
PD-1 inhibitors, both humanized IgG4s, nivolumab (OPDIVO, Bristol-Myers Squibb, New
York, NY, USA), and pembrolizumab (KEYTRUDA, Merck Sharp & Dohme, Kenilworth, NJ,
USA), plus durvalumab (high affinity engineered IgG1 versus PD-L1). The phase III studies
for nivolumab (CHECKMATE-141) [89] and pembrolizumab (KEYNOTE 040) [90] both
showed a survival benefit as compared to standard monotherapy for diseases progressing
less than 6 months after a platinum-based CT [88–90]. Long term results of the nivolumab
CHECKMATE-141 study (minimum follow-up 24.2 months) confirmed a survival advan-
tage with the 2-year rate almost 3-fold more, an increased durability of response, and much
less toxicity [91]. For the KEYNOTE 040 study, the primary endpoint of increased OS was
met with a median of 8.4 months for the pembrolizumab arm compared to 6.9 months in
the standard arm, respectively, and first-year survival comparison was 37% vs. 26.5%. The
response rate is moderate at 14.6% in the pembrolizumab arm vs. 10.1% in the SOC arm,
but with a very long median response duration in the pembrolizumab arm of 18.4 months
and a better toxicity profile.
It is important to point out that any direct comparison of these trials is complicated
by subtle differences in the patients recruited and the treatments provided in the standard
therapy arms. However, the efficacy of these drugs in patients with R/M HNSCC revealed
a relatively low overall response rate with no difference in response between HPV-positive
and HPV-negative cancers. By apparent contrast, durvalumab in the EAGLE phase III
study showed no significantly increased OS compared to SOC treatment, but this negative
result probably results at least in part from unexpectedly good outcome in the control
arm (SOC) patients. Interestingly, there is a lot of mortality in the early stages of this
trial in the immunotherapy arm patients, but the fraction of these patients who survived
showed increased duration of responses, better survival at 2 years, plus reduced toxicity to
durvalumab relative to the SOC arm [92].
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Table 2. Key immune checkpoint inhibitor clinical efficacy trials for HNSCC.
Study [Ref] (No of Patients) Drug v IC or SOC OS: Median (mo) HR(p Value)
1 Year OS (%) 2 Year OS
(%)





% Toxicity Grade 3
CHECKMATE-141 [84,86]
(n = 506)
Open Label, Randomized Phase
3 Trial of Nivolumab vs.













9.7 v 4.0 13.1 v 35.1
KEYNOTE-040
[85] (n = 495)
Phase III Randomized Trial of











18.4 v 5.0 13 v 36












18.4 v 10.3 2.1 v 3.7NA
17.9 v 17.3
12.9 v 3.7 10.1 v 24.2
Legend: NCT = National Clinical Trial; IC = Investigators Choice; HR = Hazard Ratio; mo = month; * statistically significant.
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Unfortunately, the impact of immune checkpoint inhibitors is somewhat limited by
the relatively low proportion of patients who respond, the need to manage potential
autoimmune toxicities in some patients, as well as the high treatment costs. This highlights
the value of a biomarker(s) that might allow for selection of patients who could most benefit
from such immunotherapies. The obvious candidate has been to investigate whether the
level of inhibitory molecule tumour expression can predict patient responses.
9. PD-L1 Expression as a Prognostic in HNSCC and in Association to HPV Status
PD-L1 expression has been widely investigated for use as a predictive marker in
several solid tumours although the results have had limited value in clinical application
thus far [93]. This is seen with HNSCC, where investigations of PD-L1 positivity within a
tumour have not yielded consistent results in seeking any correlation to clinical responses.
This reflects the problems derivative from the heterogeneity of tumours included in differ-
ent studies (HNSCC, OPSCC, HPV status), the associated patient treatment schedules, as
well as the reagents and detection methodologies, the definitions of positivity, the cut-off
levels used, and the scoring system with inclusion of tumour cells alone (TPS: tumour
proportion score) or all relevant cells expressing PD-L1 (CPS: combined proportion score).
In addition, our current understanding of the biology of immune checkpoint control and
the mechanisms of the agents that block these pathways is still very limited.
Even investigating the more homogeneous OPSCC tumours and stratifying by HPV
status has been challenging for integration and interpretation of simple density measures
of different cell types showing PD-L1 expression in TME with clinical outcomes to SOC.
For example, populations identified as CD8+ T cells and CD68+ macrophages were both
higher in HPV-positive compared to HPV-negative OPSCC. However, when subpopula-
tions were identified with additional markers of the checkpoint pathway CD8+/PD-1 T
cells were at similar levels but the proportion of CD68+/PD-L1/macrophages was lower
in HPV-positive compared to HPV-negative OPSCC [94]. Indeed, in HPV-negative OPSCC
patients, the increased PD-L1/macrophage levels were associated with better outcome [94].
Instead of simple enumeration of cell densities, analysing the spatial organisation of
cells in the TME may be able to provide a more “functional” measure of immune regulation.
Thus, an automated analysis pipeline was used to quantify the potential of T cells to
interact with PD-L1 expressing cells in the TME. An algorithm was used that discarded
artefacts and scanning errors, performed cell segmentation, and determined events defined
by the proximity between cell subsets employing the hypothesised interaction distribution
method. The results showed that a high frequency of spatial interactions between CD8+-
or PD-1-marked T cells and PD-L1-positive cells were prognostic for poor overall survival
in patients with HPV-negative OPSCC [95]. Previous analyses of the same cohort using
density measures of PD-L1 expression with CPS >5% had concluded that only stromal PD-
L1 was prognostic in HPV-negative OPSCC [94]. However, none of these results support
the notion that PD-L1 expression levels link to improved outcome in a consistent way.
10. PD-L1 Expression to Stratify Treatment
In the context of immune checkpoint inhibitor trials in HNSCC, IHC-assessed PD-
L1 expression was scored on either tumour cells alone (TPS) or also including tumour-
infiltrating immune and stromal cells (CPS). For example, in CHECKMATE-141 [89,91],
a PD-L1 tumour membrane expression of ≥1% expression was the positive definition
using the Dako PD-L1 IHC 28–8 pharm Dx test. This concluded that there was a greater
positive impact on outcome for nivolumab-treated patients compared to those receiving
standard therapy if their tumours expressed PD-L1 and compared to those with PD-L1-
negative tumours. However, by 2 years of follow-up, checkpoint inhibitor treatment also
showed evidence of benefit in the patients with PD-L1-“negative” tumours. Refining the
definition of positivity for the PD-L1 expression scores of ≥1% vs. ≥5% vs. ≥10% showed
increased overall response rates, but did not alter the OS measures [89]. Clearly, this
biomarker methodology cannot identify all the patients that could respond to treatment.
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When the presence of PD-L1-expressing tumour-associated immune cells were included
in the scoring, this was shown to be more predictive of benefit than tumour cell PD-L1
expression alone, but this was complicated by the observation that the predicted increased
benefit from nivolumab compared to SOC was greater in tumour cell PD-L1-negative
patients [91]. For KEYNOTE-040, PD-L1 tumour expression was assessed by a different test
(Dako PD-L1 IHC 22C3 pharmDx). In exploratory analyses, not adjusted for multiplicity,
an interaction between the treatment effect for OS and PD-L1 expression was seen, with
the benefit of pembrolizumab greater in patients with a CPS ≥ 1 compared to CPS < 1; this
was also seen when stratifying tumours by TPS ≥ 50% versus < 50%. These preliminary
results suggest benefits on PFS and objective response of checkpoint inhibitor versus SOC
therapy which are greater in patients whose tumours had higher PD-L1 expression [90].
Further studies assessing PD-L1 positivity (CPS ≥ 1) showed a significant improvement
in OS compared to SOC [3,96]. These phase III studies in patients with R/M HNSCC for
nivolumab (CHECKMATE-141) and pembrolizumab (KEYNOTE-040) compared to SOC
led to FDA/EMA approval; the EMA subsequently restricted pembrolizumab to patients
with tumours scoring TPS ≥ 50% [3].
In a further development, the KEYNOTE-048 study investigated the use of pem-
brolizumab as first-line treatment for platinum-sensitive patients with R/M disease. This
showed that compared to SOC, CT (platinum + 5-FU), pembrolizumab, plus CT provided a
better OS in the PD-L1 CPS ≥ 20, CPS ≥ 1, and total populations, while pembrolizumab
monotherapy demonstrated superior OS in the CPS ≥ 20 and≥ 1 populations and was
non-inferior in the total population [3,97]. The FDA has approved pembrolizumab for
CPS ≥ 1 patients and for pembrolizumab and CT for the entire population, but the EMA
restricted its use to CPS ≥ 1 patients receiving pembrolizumab alone or with CT. The 2-year
survival rates of 29–35% are significantly improved compared to the EXTREME regimen,
notwithstanding the reduced toxicity. Response rates are still less than 23% with 40.5%
progression for pembrolizumab alone, so there is still plenty to do to increase efficacy and
focus such immunotherapy. Importantly, the response rate to pembrolizumab plus CT of
35% does not improve on that delivered by CT alone while the nearly doubled survival
rate of 30%–35% is about the same as the immunotherapy alone [97].
Here, only some of the pivotal clinical trials have been described to highlight the
issues of utilising biomarkers in immune checkpoint inhibitor treatment selection. There
are more details of the evolution of these, and many other supporting studies in Borel et al.
2020 [88]. While there is a general correlation of PD-L1 tumour expression with immune
checkpoint inhibitor efficacy in R/M HNSCC, with improved predictive quality when
using CPS, it is still clear that some patients whose tumours area scored as PD-L1-negative
can still benefit from treatment. Comparative studies of reagents and methodologies are
being conducted, but so far without any definitive conclusions.
11. General Reflections on Biomarkers for OPSCC
It does appear that right now there is a limited value in IHC-based assessments of
PD-L1 expression for accurately determining treatment options. The challenge is how to
interpret measures (e.g., density) of different populations of immune and other cell types
and their functional status from 2D snapshots accounting proximity and the presence of
soluble factors that will be integrated to contribute to “responsiveness”. Ultimately, multi-
plex IHC techniques will have a limit of simultaneously analysable markers even when
utilising automated scanning and scoring systems. How likely is any combination of factors
measured by such mainly IHC studies ever going to reflect the nuances of the multitude of
components that are dynamically integrating to determine potential responsiveness to a
checkpoint inhibitor in an OPSCC patient? Given the number of other known regulatory
pathways active in the TME and systemically, plus undoubtedly unknown unknowns,
the failure to identify a really specific measure of PD-L1 expression for very accurate
prognostics and treatment deployment in HNSCC (OPSCC) is probably understandable.
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In other words, current biomarkers like those being investigated above do not provide
a sufficiently granular distinction between one tumour and another to achieve effective
stratification of treatment. It follows that until studies can be conducted with more “gran-
ular” eligibility (biomarker profile) for checkpoint therapy, it will be difficult to identify
cohorts who can best benefit from this approach.
The analyses for PD-L1 so far have been based on a reasonable hypothesis whereby
more PD-L1 expression in the tumour reflects a history of undermined immune control
which is available to be released on checkpoint inhibition. Some have hypothesised and
found general evidence supporting the idea that there is a correlation between the number
of accumulated mutations, thereby generating potential tumour antigens, and the response
to checkpoint inhibitors [98–101]. T cell infiltration in tumours is also well correlated
with improved outcomes with Immunoscore providing useful prognostic information in
colorectal cancer [36].
Future progress in determining better prognostic and therapy application tools may
require the integration of additional classification features of a tumour incorporating the
mutational load, (epi) genetic background (microsatellite instability) status, chromosomal
instability, and CpG island methylator phenotype status, as well as risk factors like virus or
other infection, UV, chemical, and physical carcinogen exposure [102]. Such investigations
emphasize the importance of the immune context but also the extent of the positive and
negative factors shaping carcinogenesis and tumour progression or control. A recent study
has focused on the balance of PD-1 positive CD8+ T and Treg cells in cancers and shown that
the ratio in the TME can predict the clinical efficacy of PD-1 blockade therapies compared
to PD-L1 expression or mutational burden [103]. It is hypothesized that a better recovery
of dysfunctional PD-1-positive CD8+ rather than Tregs is required for tumour regression.
This once again highlights the relative lack of predictive power with such approaches.
The functionality of infiltrating T cells effectors induced by chronic stimulation, typi-
cally viral, can also lead to a state of exhaustion [104]. Such T cells over-express several
inhibitory receptors (e.g., PD-1), exhibit major changes in T cell receptor and cytokine
signalling pathways, have changes in expression of genes controlling chemotaxis, adhesion,
and migration, and show distinct transcriptional signatures and various metabolic and
bioenergetic deficiencies [105,106]. The continuous stimulation of naïve T cells in the local
lymph node leads to a skewed population of CD8+ effectors at lesion sites with functional
T cell exhaustion progressive but distinct from anergy [107]. A homeostatic mechanism
is invoked that aims to protect the repertoire of antigen-specific T cells by generating a
stem cell-like CD8+ non-recirculating population which resides in T cell zones of lym-
phoid tissues along with the naïve T cells [108]. They are quiescent but have proliferative
potential and provide a means to sustain supply of activated specific T cells in a chronic
situation. Tcf-1 is critical for generation of this PD-1-positive CD8+ T cell subset which can
permit self-renewal as well as differentiate into more terminally differentiated cells that
down-regulate Tcf-1 and with a transitory population of CD101-negative Tim3-positive
cells can convert to CD101-positive Tim-positive T effectors. Importantly, PD-1 pathway
blockade increases the numbers of transitory cells, suggesting that these cells play a crit-
ical role in PD-1-based immunotherapy [106]. While these novel sets of both terminally
differentiated and stem-like CD8+ T cells have mostly been investigated in chronic virus
infection they have also been detected in human tumours. Importantly, they are found in
pseudo-antigen-presenting-cell niches within some tumours and, interestingly, patients
with progressive disease seem to lack these immune niches and this correlates with low
levels of T cell infiltration [109,110]. It appears that the mechanisms underlying checkpoint
blockade depend not on a simple reversal of T cell exhaustion but requires the expansion
of the stem-like population [110–112]. When these cells are released from their quiescence,
they are subsequently receptive to antigen presentation, and can mobilize, proliferate, and
functionally differentiate. The checkpoint blockade may also influence effector function
at the target sites with increased killing and cytokine release. A greater understanding of
how to best mobilize this unique stem-like population in a chronic viral-driven tumour
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will be important to maximizing the impact of therapies which seek to harness the immune
response [41].
Finally, using dissociated OPSCC tissues and more powerful techniques based on mass
spectrometry and/or single-cell RNA analyses may provide for the use of more co-markers
to improve precision in identifying particular populations like CD103+ tissue-resident T
cells whose presence and function may be pivotal in anti-tumour immunity [74,112–115].
However, the analyses may be compromised by the process of recovery altering the cellular
RNA, etc. expression status. Nevertheless, such approaches could be useful in revealing
important features of the TME critical to outcomes in response to available treatments.
There are also platforms available which can integrate multiplexed expression data (RNA,
protein) from particular individual cells in the context of the tissue with the option to look
for dynamic changes seen in disease progression or treatment [116–118].
On the other hand, the practicality of these more sophisticated techniques to routine
assessment for either prognostics or treatment allocation is more doubtful through logistic
and cost issues, at least in the short term. This article has therefore concentrated on immune
factors assessed locally in the context of checkpoint inhibitors as a central pivot in current
therapeutic treatments in OPSCC. More global analyses of gene expression patterns have
been applied to define different HNSCC subtypes incorporating biological characteristics
and de-regulated signalling pathways as immunoreactive, inflammatory, HPV-like, classi-
cal, hypoxia-associated, and mesenchymal with the latter two more aggressive [103]. More
information does not necessarily provide useful clinical insights if the subgroups are too
numerous and still heterogeneous [119,120].
12. Types of Combination HNSCC (OPSCC) Therapies under Investigation
In the context of checkpoint inhibitor treatments for HNSCC (OPSCC) there is estab-
lished proof of principle for improved management which warrants continued research for
useful biomarkers enabling better prognostics and treatment deployment. To a large extent,
biomarker studies are mostly an add on, or evaluated post hoc, in clinical trials primar-
ily investigating the efficacy of increasing numbers and varieties of immune checkpoint
inhibitors delivered in combination with variations of SOC or with other experimental
immuno-therapeutic strategies. It is sobering to consider that a fundamental re-evaluation
of the influence of radiation and chemical treatment protocols on both local and systemic
functional immunity should really be reconsidered in the context of the deployment of
immunotherapies aimed at either recovery of an existing immune response or the induc-
tion of novel anti-tumour activity [121–123]. The ongoing clinical studies of checkpoint
inhibitors in HNSCC have recently been reviewed by the van der Burg group [46] and
can be comprehensively accessed at Clinicaltrials.gov [124]. The extent and diversity of
approaches reveals a somewhat scatter-gun approach which may luck out but could also
just consume resources for a minimal gain. A summary of a selection of ongoing later
phase 2/3 trials outlining the design, size, patient eligibility criteria, primary endpoints,
and their timelines is given Table 3. These relatively few examples illustrate the challenges
of designing meaningful clinical studies to investigate PD-1/PD-L1 pathway inhibition in
the context of suboptimal SOC with a view to improved patient management/outcomes.
Is it the case that this activity is only likely to further progress incrementally for highly
defined groups and that for the majority of patients real progress will require new treatment
paradigms based on new knowledge?
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Table 3. Selected phase 2/3 clinical trials involving immune PD-1/PD-L1 pathway inhibitors in HNSCC(OPSCC).
NCT (ClinicalTrials.Gov) Design Treatment Arms Patient Eligibility Primary Endpoints Start (Month/Year) Status
03082534
Open-label, non-randomized,
multi-arm phase II trial of
pembrolizumab combined with














83 HNSCC not amenable to
curative intent therapy.
ORR at: 6 months
Proportion of patients with





Randomized phase II/III trial of
adjuvant RT with cisplatin,
docetaxel-cetuximab, or
cisplatin-Atezolizumab
(anti-PD-L1) in HR HNSCC.
First select the better
docetaxel-based exptl arm to DFS
over control arm 1. (Phase II)
(COMPLETE 3/2020)
To determine if combination of
docetaxel-cetuximab & IMRT is
superior for OS compared to
standard cisplatin & IMRT in
adjuvant treatment (Phase III) To
determine if combination of
atezolizumab, cisplatin, & IMRT
is superior in terms of OS
compared to standard cisplatin &
IMRT in the adjuvant treatment
HPV-negative HNSCC (Phase III)
Experimental: Arm 1 (IMRT,
cisplatin)
Experimental: Arm 2 (IMRT,
docetaxel)
Experimental: Arm 3 (IMRT,
docetaxel, cetuximab)
Experimental: Arm 4 (IMRT,
cisplatin, atezolizumab)
613 HPV negative HNSCC DFS (Phase II) up to 7 yearsOS (Phase III) up to 7 years
3/2013
Active
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Table 3. Cont.





by surgical resection &
risk-adapted adjuvant therapy
for treatment of LA & surgically
resectable HNSCC
Experimental: Low Risk
Part 1: 6 weeks of induction
carboplatin chemotherapy;
Part 2: 2–6 weeks
post-induction, tumour
imaging, & surgical resection;
Part 3: adjuvant durvalumab
Experimental: Medium Risk
Part 1: 6 weeks of induction
carboplatin chemotherapy in
combination with
durvalumab; Part 2: 2–6
weeks post-induction,
tumour imaging & surgical





6 weeks of induction
carboplatin chemotherapy in
combination with
durvalumab; Part 2: 2–6
weeks post-induction,
tumour imaging & surgical
resection; Part 3 IMRT
concurrent with cisplatin or












HNSCC amenable to surgical
resection approximately 8-12
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Table 3. Cont.
NCT (ClinicalTrials.Gov) Design Treatment Arms Patient Eligibility Primary Endpoints Start (Month/Year) Status
03258554
Randomized phase II/III trial of
radiotherapy with concurrent
durvalumab vs. radiotherapy








Not suitable for cisplatin
treatment
DLT up to 4 weeks after RT
PFS (Phase II) up to 3 years




Phase II randomized trial of










114 HNSCC HPV + (p16)
high-intermediate risk
disease
PFS up to 3 years 12/2017Active
03410615
Non-comparative, randomized,
phase II study of cisplatin plus
















closed to accrual in 2019)
180 LA HPV + (p16) HNSCC 3 year event-free survival 1/2018 active
03468218
Studies effects of pembrolizumab
& cabozantinib (protein kinase





53 HPV + HNSCC ORR 3/2018Active
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NCT (ClinicalTrials.Gov) Design Treatment Arms Patient Eligibility Primary Endpoints Start (Month/Year) Status
03618134
Studies the side effects & how
well stereotactic body radiation
therapy & durvalumab
(anti-PD-L1) with or without
tremelimumab (anti-CTLA4)
before surgery work in treating
participants with HPV+ OPSCC







82 HPV+ (p16 IHC) OPSCC.
T0-3 disease with gross
disease amenable to R0
resection (TORS eligible);
N0-N2b, disease confined to 2
cervical LN levels if adjacent.
Phase 1 safety-related
adverse events up to 90 days
PFS (Phase II from enrolment
to the first occurrence of
disease progression up to 2




Randomized, phase II testing
efficacy of Ibrutinib (tyrosine
kinase inhibitor) in combination
with either nivolumab or
Cetuximab (EGFR inhibitor) in
R/M HNSCC
Arm A: Ibrutinib +
Cetuximab
Arm B: Ibrutinib +
Nivolumab
39 R/M HNSCC not yet
treated with EGFR inhibitors
Efficacy of Combined





randomized, phase 2 study in
which subjects will be randomly
assigned 1:1 to cemiplimab plus






194 R/M OPSCC HPV16 +,
PD-L1+ (CPS ≥ 1). Patients
suitable for first-line PD-1
blocking antibody & with








Studies side effects & best dose of
ipilimumab (anti-CTLA4),





(p16+, HPV DNA or RNA+)
DLTs relating
immunotherapy. For phase II:





Does 2yr PFS improve with add






40 stage 3 (p16+) OPSCC PFS up to 2 years 2/2019Active
03952585
Does a reduced dose of radiation
therapy & nivolumab (anti-PD-1)
work as well as standard dose
radiation therapy & cisplatin
OPSCC patients?
Arm I: IMRT, IGRT, cisplatin
Arm 2: Reduced IMRT, IGRT,
cisplatin
Arm 3: IMRT, IGRT,
nivolumab
711 stage 1-II (p16+) OPSCC PFS (Phase II/III) up to 6years; QOL
5/2019
Active
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Table 3. Cont.
NCT (ClinicalTrials.Gov) Design Treatment Arms Patient Eligibility Primary Endpoints Start (Month/Year) Status
03978689
Phase 1 dose escalation &
expansion study evaluating the
safety, anti-tumour effect, &
immunogenicity of CUE-101 as
monotherapy treatment in
2ndline or CUE-101 combination
therapy with pembrolizumab in
first-line HPV16+ R/M (HNSCC)
patients. CUE-101 is a novel
fusion protein designed to
activate & expand a population




trial, to assess safety &
tolerability of CUE-101 in
subjects with R/M HNSCC in
2nd-line setting, to determine
MTD or recommend Phase 2









biological effects of CUE-101
in combination with
pembrolizumab in R/M
HNSCC patients in first-line
setting.
85 patients, HPV 16 + (RNA
ISH & p16 IHC) R/M
HNSCC progressed following
at least 1 prior systemic
therapy.
HLA A * 0201 genotype
The primary objectives of the
Part A&B, first-in-human
trial, are to assess the safety
and tolerability of CUE-101 in
subjects with
recurrent/metastatic HNSCC
in the second-line setting and
to determine the maximum
tolerated dose or
recommended Phase 2 dose





Testing ISA101b (HPV 16 E6/E7
synethetic long peptide vaccine)
plus cemiplimab in subjects who
have progressed on prior
anti-PD-1 therapy
Single arm: ISA101b 3 times
plus cemiplimab every 3
weeks for up to 24 months
86 PD metastatic HPV16 +
OPSCC at primary site & LNs
limited to neck. Patients had
at least 4 doses anti-PD-1
antibody with or without
chemotherapy within 6
months.
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NCT (ClinicalTrials.Gov) Design Treatment Arms Patient Eligibility Primary Endpoints Start (Month/Year) Status
04634825
Study of enoblituzumab







block PD-1 & LAG-3 checkpoint
molecules) given as first-line
treatment to patients with R/M
HNSCC
Arm 1: retifanlimab cohort
(Enoblituzumab +
retifanlimab)
Arm 2: tebotelimab cohort
Enoblituzumab + tebotelimab








tebotelimab at 28 months







Studies effect of pembrolizumab
in combination with radiation
therapy or pembrolizumab alone
or SOC (chemotherapy plus




Arm B: cisplatin, carboplatin,
IMRT, PBRT
Arm C: pembrolizumab
R/M HNSCC in a previously
radiated field after surgery.
HR disease with tumour
PD-L1 (CPS) ≥ 1
OS at 2 years




Studies efficacy & safety of
sintilimab (anti-PD-1) in
combination with carboplatin &
nab-paclitaxel in patients with
oral cavity or OPSCC who are
about to undergo surgery.
Drug: sintilimab, paclitaxel,
carboplatin
Treatment repeats every 21





OSCC or OPSCC which is
planned for treatment with
curative intent including
surgical resection.
Adverse events up to 90 days
Pathologic response to
neoadjuvant treatment in
resected tumour & lymph
nodes compared to historical
SOC tumours up to 6 weeks
12/2020
Active
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NCT (ClinicalTrials.Gov) Design Treatment Arms Patient Eligibility Primary Endpoints Start (Month/Year) Status
04862650
Studies effect of cemiplimab
(anti-PD-1) in combination with
low-dose paclitaxel & carboplatin
in R/M HNSCC
Single Arm: cemiplimab,
paclitaxel, carboplatin) 33 R/M HNSCC ORR at 12 weeks NYA
04858269
Effects of carboplatin & paclitaxel
plus pembrolizumab (anti-PD-1)
in HNSCC patients unable to
take 5FU
Single Arm: Pembrolizumab
+ carboplatin + paclitaxel in
outpatient setting
35 R/M HNSCC not suitable
for infusional 5FU








Legend: [124] Abbreviations: RT, radiotherapy; IMRT, intense modulated RT; IGRT, image guided RT; DLT, dose limiting toxicity; CRR, complete response rate; ORR, overall response rate; PBRT, pencil beam RT;
MTD, maximum tolerated dose; PL, pharmacokinetics; ISH, in situ hybridization; TORS, trans oral robotic surgery; DFS, disease control rate; NYA, not yet activated; OS, overall survival; PFS, progression-free
survival; QOL, quality of life; IHC, immunohistochemistry. Drugs: PD-1 blocking antibodies: -nivolumab, pembrolizumab, cemipliamb, sintilimab; PD-L1 blocking antibodies: -retifanlimab, atezolizumab,
durvalumab. Other immunotherapeutic agents: tebotelimab (bispecific DART® molecule designed to independently or co-ordinately block PD-1 & LAG-3 checkpoint molecules; enoblituzumab (anti-B7-H3
targets B7 family immune regulatory molecule); anti-CTLA4 antibodies: ipilimimab, tremelimumab. Kinase inhibitors: ibrutinib, cabozantinib; Other immunotherapeutic agents: ISA101b, HPV 16 E6/E7
synthetic long peptide vaccine; CUE-1 is a fusion protein nased on an E7 specific HLA * 02 restricted TCR expressed in T cells expanded ex vivo and adoptively transferred. Chemotherapeutic drugs: paclitaxel,
carboplatin, cisplatin, and docetaxel.
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13. Final Reflections
Many drugs targeting costimulatory and coinhibitory immune checkpoint molecules
have now been developed. How conventional therapy influences these pathways in differ-
ent immune cell subsets and beyond during the course of treatment is largely unknown.
Some recent studies have begun to investigate such effects and may help to identify possible
novel combinational therapeutic approaches [125,126]. The caveat is that these regulatory
networks are often interactive (cellular and extracellular) and provide a redundancy that
allows for fine tuning in responses, so insight from only a few biomarker assessments
may be relatively limited. Combination treatments based on understanding the influence
of immune deviation on tumour survival have utilised initial chemotherapy to provide
for a reduction in the levels of MDSCC followed by HPV 16 oncogene vaccination which
is then more effective at stimulating anti-tumour T cell responses, enabling prolonged
survival [127,128]. Likewise, checkpoint blockade in combination with tumor-specific vac-
cination of patients with HPV16-related cancer has been attempted and has shown some
promise [129]. Going forward, especially by utilising technology advances, additional mod-
ification strategies will be investigated to improve targeting and stimulation of cytotoxic T
cell-based immune responses for optimal development of combination therapies [130,131].
A useful biomarker must identify a reasonable proportion of the patients where as-
signment of the associated treatment option has a high certainty of clinical value and where
others are not excluded from this potential benefit. Ultimately, protocols which provide the
best options for maximising response and minimising toxicity for the largest number of
patients to be effectively treated are empirically determined in iterative clinical studies. The
more factors used to refine the options for therapy selection, the more stratification of the
patients occurs, ultimately leading to individually personalized medicine which must drive
up costs even if logistically deliverable. Hopefully, the extensive testing of combinations of
therapeutic approaches by types and sequencing will fuel the next evolution of treatment
for OPSCC (HNSCC), albeit through the stalwarts of much medical progress, empiricism,
and serendipity.
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